Binds Virus Or Component Or Product Thereof (e.g., Virus-associated Antigen, Etc.) Patents (Class 530/389.4)
  • Publication number: 20150132277
    Abstract: Isolated monomeric aminoacyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
    Type: Application
    Filed: October 9, 2014
    Publication date: May 14, 2015
    Inventors: Paul Schimmel, Xiang-Lei Yang, Bonnie Slike
  • Publication number: 20150104466
    Abstract: The present invention relates to methods and compositions for inhibiting the entry of viruses, such as herpesviruses into a host cell. A conserved viral integrin-binding gB disintegrin-like domain has been identified that engages integrins and facilitates viral internalization into the host cell. Therefore, methods and compositions, such as antiviral agents encompassing the conserved gB disintegrin-like domain and antibodies thereto are described. These active agents interfere with the interaction between virions and cellular integrins, thereby inhibiting viral infection of a host cell.
    Type: Application
    Filed: October 16, 2013
    Publication date: April 16, 2015
    Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Teresa Compton, Adam L. Feire
  • Publication number: 20150104480
    Abstract: A method of producing a virus like particle (VLP) in a plant is provided. The method comprises introducing a first nucleic acid and a second nucleic acid into the plant, or portion of the plant. The first nucleic acid comprises a first regulatory region active in the plant and operatively linked to a nucleotide sequence encoding a structural virus protein. The second nucleic acid comprises a second regulatory region active in the plant and operatively linked to a nucleotide sequence encoding a channel protein, for example but not limited to a proton channel protein. The plant or portion of the plant is incubated under conditions that permit the expression of the nucleic acids, thereby producing the VLP.
    Type: Application
    Filed: September 28, 2012
    Publication date: April 16, 2015
    Inventors: Marc-Andre D'Aoust, Manon Couture, Louis-Philippe Vezina
  • Publication number: 20150098948
    Abstract: The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 9, 2015
    Inventors: Andres G. Grandea, III, Gordon King, Thomas C. Cox, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Phil Hammond
  • Publication number: 20150079581
    Abstract: The present invention is a test kit for rapidly diagnosing influenza according to the principles of immunochromatography, and the purpose thereof is to provide a test kit for the influenza A virus in which the sensitivity in detecting the influenza A virus is greater than in conventional test kits, and a determination of “positive” is obtained stably and with high precision at an earlier time during the onset of influenza symptoms. The present invention pertains to a kit for detecting influenza A virus, in which an antibody that is in solid phase in the chromatographic medium enters into an antigen-antibody reaction with native nuclear proteins of the influenza A virus, but in Western blots the antibody does not enter into antigen-antibody reactions with full-length nuclear proteins of the influenza A virus that have been separated using SDS-polyacrylamide gel electrophoresis.
    Type: Application
    Filed: March 29, 2013
    Publication date: March 19, 2015
    Inventors: Hisahiko Iwamoto, Hiroko Kawamoto, Shinichi Kato
  • Patent number: 8961978
    Abstract: The present disclosure relates to binding molecules, such as human monoclonal antibodies, that bind to an epitope in the stem region of hemagglutinin of influenza A viruses of phylogenetic group 1 and group 2, as well as influenza B viruses, and have a broad neutralizing activity against such influenza viruses. The disclosure provides nucleic acid molecules encoding the binding molecules, their sequences and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of influenza A viruses of phylogenetic groups 1 and 2, as well as influenza B viruses.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: February 24, 2015
    Assignee: Crucell Holland B.V.
    Inventors: Theodorus Hendrikus Jacobus Kwaks, David Adrianus Theodorus Maria Zuijdgeest, Ronald Vogels, Robert Heinz Edward Friesen
  • Publication number: 20150037352
    Abstract: This disclosure relates to novel peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use.
    Type: Application
    Filed: October 16, 2014
    Publication date: February 5, 2015
    Inventors: Zachary Shriver, Karthik Viswanathan, Vidya Subramanian, Sasisekharan Raguram
  • Publication number: 20150030587
    Abstract: Methods of treating a head and neck cancer are disclosed.
    Type: Application
    Filed: February 11, 2014
    Publication date: January 29, 2015
    Applicant: FOUNDATION MEDICINE, INC.
    Inventors: Chris Hendrik Boshoff, Timothy Robert Fenton, Matthias Alexander Lechner, Philip James Stephens, Matthew J. Hawryluk, Garrett Michael Frampton, Roman Yelensky
  • Publication number: 20150010566
    Abstract: The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for multiple influenza A virus subtypes. The invention further relates to the use of such antibodies for diagnosis of an influenza A virus infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of an influenza A virus infection.
    Type: Application
    Filed: December 3, 2012
    Publication date: January 8, 2015
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Arjen Quirinus Bakker
  • Publication number: 20150004190
    Abstract: Novel antibodies and peptides relating to HIV are disclosed, as are vaccine compositions containing such antibodies and peptides. The compounds and compositions of the invention are of use in prevention and treatment of HIV, and in particular for inducing mucosal immunity to HIV.
    Type: Application
    Filed: January 25, 2013
    Publication date: January 1, 2015
    Inventors: Morgane Bomsel, Daniela Tudor
  • Publication number: 20140377279
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: September 13, 2013
    Publication date: December 25, 2014
    Applicant: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • Publication number: 20140370032
    Abstract: The invention relates to a method for isolating a polypeptide reactive to influenza A hemagglutinin, comprising the steps of preparing a library of nucleic acid sequences, wherein each member of said library is attached to a polypeptide sequence encoded thereby, selecting members of said library by contacting the members with a panning antigen, wherein the panning antigen comprises a hemagglutinin stem region polypeptide sequence, subsequently removing members unreactive to the panning antigen, and selecting a member of said library by determining its binding to at least 5 influenza A hemagglutinin subtypes of subtype group 1 and 2. The invention further relates to polypeptides, particularly antibodies, obtainable by this method, that neutralize at least five influenza A subtypes of subtype group 1 and 2, to vaccines and uses thereof.
    Type: Application
    Filed: August 27, 2012
    Publication date: December 18, 2014
    Applicant: UNIVERSITAT ZURICH
    Inventors: Lars Hangartner, Arkadiusz Wyrzucki
  • Publication number: 20140363459
    Abstract: The present invention relates to synthetic proteins and the uses thereof. More particularly, the invention relates to synthetic Circovirus type capsid proteins with improved properties. These proteins, or the coding nucleic acids, are useful e.g., to generate antibodies, immunogen compositions, or vaccines. The invention further relates to methods for treating and/or preventing PCV2-associated diseases in mammals using said proteins, nucleic acids or compositions. The invention also relates to compositions and methods for detecting PCV2 in a sample, using the above proteins, nucleic acids, or antibodies.
    Type: Application
    Filed: August 31, 2012
    Publication date: December 11, 2014
    Applicant: Ceva Sante Animale
    Inventors: Zoltan Penzes, Anna Kollar, Marianna Ivok
  • Publication number: 20140341929
    Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.
    Type: Application
    Filed: July 3, 2014
    Publication date: November 20, 2014
    Inventors: Ronald Vogels, Theodorus H.J. Kwaks
  • Patent number: 8889137
    Abstract: The invention relates to an anti-HSV antibody as defined in the claims, a pharmaceutical composition comprising of an effective amount of the said antibody, an expression vector comprising of a nucleotide sequence which encodes the said antibody, a host cell comprising of the said nucleotide sequence, a hybridoma cell capable of producing the said antibody and the use of the said antibody as a drug, in particular to use for the manufacture of a drug for the prophylactical or therapeutical treatment of HSV-associated diseases in a subject; as defined in the claims.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: November 18, 2014
    Assignees: Universität Duisberg Essen, Rheinische Friedrich Wilhelms —Universität Bonn
    Inventors: Michael Roggendorf, Anna-Maria Eis-Hübinger, Jürgen Krauss, Karl Eduard Schneweis, Michaela Arndt, Adalbert Krawczyk, Evelyn Exner, Martin P. Däumer, Edelgard Schneweis
  • Publication number: 20140335126
    Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV), and in particular to a vaccine for HIV-1 and to methods of making and using same.
    Type: Application
    Filed: December 5, 2012
    Publication date: November 13, 2014
    Inventors: Barton F. Haynes, Huaxin Liao, Jerome Kim, Nelson Michael, Susan B. Zolla-Pazner
  • Publication number: 20140328862
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Application
    Filed: May 17, 2012
    Publication date: November 6, 2014
    Applicants: THE ROCKEFELLER UNIVERSITY, California Institute of Technology
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • Publication number: 20140328797
    Abstract: The invention provides isolated fully human monoclonal anti-HRV antibodies, as well as method of making and using these antibodies. Anti-HRV antibodies of the invention prevent or treat subjects having HRV-infections, and related diseases, including, but not limited to, the common cold, nasopharyngitis, croup, pneumonia, bronchiolitis, asthma, chronic obstructive pulmonary disease (COPD), sinusitis, bacterial superinfection, and cystic fibrosis.
    Type: Application
    Filed: April 28, 2014
    Publication date: November 6, 2014
    Inventors: Po-Ying Chan-Hui, III, Kristine Swiderek
  • Publication number: 20140302063
    Abstract: The present invention relates to unique CDR3 amino acid sequences, and to antibodies comprising said sequences. Also provided are therapeutic applications of said antibodies for use in treating or preventing influenza infection, diagnostic applications of said antibodies for use in detecting influenza virus, potency testing of influenza virus vaccines, and screening applications of said antibodies for use in designing a universal influenza vaccine.
    Type: Application
    Filed: September 3, 2012
    Publication date: October 9, 2014
    Applicant: The Secretary of State for Health
    Inventor: Simon Hufton
  • Publication number: 20140302062
    Abstract: The present invention relates, in general to herpes simplex virus (HSV) and, particular, to antibodies that are specific for glycoprotein D (gD) of HSV. The invention also relates to prophylactic and therapeutic uses of such antibodies.
    Type: Application
    Filed: April 9, 2012
    Publication date: October 9, 2014
    Applicants: U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND, DUKE UNIVERSITY
    Inventors: Barton F. Haynes, Hua-Xin Liao, M. Anthony Moody, Georgia D. Tomaras, Jerome Kim, Nelson Michael
  • Publication number: 20140271653
    Abstract: The present invention provides fully human antibodies that bind to respiratory syncytial virus F protein, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for preventing fusion of the virus with the cell membrane and preventing cell to cell spread of the virus, thereby providing a means of preventing the infection, or treating a patient suffering from the infection and ameliorating one or more symptoms or complications associated with the viral infection. The antibodies may also be useful for diagnosis of an infection by RSV.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Anne Gurnett-Bander, David Perez-Caballero, Sumathi Sivapalasingam, Xunbao Duan, Douglas MacDonald
  • Patent number: 8828399
    Abstract: Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: September 9, 2014
    Assignee: The Trustees of Princeton University
    Inventors: Thomas Shenk, Dai Wang
  • Patent number: 8828400
    Abstract: Described is an antibody or an antigen binding fragment thereof specifically binding to a full or empty H-1 parvovirus capsid. Such an antibody is useful for various diagnostic and therapeutic methods, e.g., for the detection/therapy of an H-1 parvovirus infection during pregnancy since parvovirus affects about 1 in 400 pregnancies and may cause fetal loss or fetal hydrops.
    Type: Grant
    Filed: December 1, 2010
    Date of Patent: September 9, 2014
    Assignee: Deutsches Krebsforschungszentrum Siftung des Öffentlichen Rechts
    Inventors: Barbara Leuchs, Kathrin Kürschner, Andrea Kuck, Marcus Müller, Silvia Münstermann, Jean Rommelaere
  • Publication number: 20140248286
    Abstract: The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.
    Type: Application
    Filed: May 12, 2014
    Publication date: September 4, 2014
    Applicant: Genentech, Inc.
    Inventors: Min Xu, Mercedesz Balazs, Ning Chai, Nancy Chiang, Henry Chiu, Zhonghua Lin, Patrick Lupardus, Gerald R. Nakamura, Hyunjoo Park, Lee Swem
  • Publication number: 20140234336
    Abstract: The present invention relates to a binding molecule having influenza A virus-neutralizing activity derived from a human B cell, and the binding molecule having the influenza A virus-neutralizing activity, according to the present invention, is a binding molecule that is derived from a B cell that is selected from the blood of a patient infected with an influenza A virus, and has neutralizing activity against influenza A viruses, and thus is useful in preventing and treating disease derived from the influenza A virus, and can be useful in diagnosing the influenza A virus by using the binding molecule according to the present invention.
    Type: Application
    Filed: September 27, 2012
    Publication date: August 21, 2014
    Inventors: Shin Jae Chang, Ki Sung Kwon, Kye Sook Yi, Hyun Joo Lee, Jae Won Jeon, Hwang Keun Jun, Min Seok Chang
  • Publication number: 20140234337
    Abstract: For many diseases due to microbes or the like, proliferation of microbes themselves is a cause of a symptom. However, there were cases where a substance released by the microbes is a cause of a symptom. In such cases, when attempting to treat a disease with an antibody, it was necessary to obtain an antibody against an antigen that is a substance causing the disease. However, it was difficult to find the underlying substance causing the disease among substances released by the microbes. An antibody (polyclonal) binding to not only an antigen but also to a substance, which is secreted by the antigen and accelerates the deterioration of a symptom, is obtained by immunizing birds with a lysis solution produced from lysing microbial cells as an antigen. Further, an antibody obtained with a surface protein of a virus as an antigen is expected to inhibit an infection by a virus.
    Type: Application
    Filed: August 9, 2012
    Publication date: August 21, 2014
    Applicants: Immortal Spirit Limited, Ostrich Pharma KK
    Inventor: Yasuhiro Tsukamoto
  • Publication number: 20140221625
    Abstract: Non-human animals with humanized immunoglobulin loci and methods of using them in vaccine design are described, as well as methods for making broadly neutralizing antibodies against infectious agents and pathogens are provided. Non-human animals with humanized immunoglobulin loci used in B-cell-lineage immunogen design in vaccine development are provided, as are methods of carrying out such design.
    Type: Application
    Filed: February 6, 2014
    Publication date: August 7, 2014
    Inventors: BARTON HAYNES, GARNETT KELSOE, ISRAEL LOWY, ARIS I. BARAS, LYNN MACDONALD, JOHN MCWHIRTER, CAGAN GURER, KAROLINA A. MEAGHER, ANDREW J. MURPHY, GEORGE D. YANCOPOULOS
  • Publication number: 20140205615
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Application
    Filed: December 23, 2013
    Publication date: July 24, 2014
    Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINE
    Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
  • Publication number: 20140193428
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Application
    Filed: December 4, 2013
    Publication date: July 10, 2014
    Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINE
    Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
  • Publication number: 20140186370
    Abstract: The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to poxvirus H3L envelope protein, and combinations thereof.
    Type: Application
    Filed: December 27, 2013
    Publication date: July 3, 2014
    Applicants: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY, KYOWA HAKKO KIRIN CO., LTD.
    Inventors: SHINICHIRO KATO, STEVE GRANGER, SHANE CROTTY, SANDRA RICKERT, LILIA KORIAZOVA, TOMOYUKI TAHARA
  • Publication number: 20140178405
    Abstract: Monomeric VHH domain derived from anti-VP6 camelid antibodies, dimeric domain, immunisation method, rotavirus detection method, vaccine composition, prevention and treatment methods for rotavirus infections, wherein said domain may be any of the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 or SEQ ID No. 4, and wherein said domains bind to protein VP6 of Group A rotavirus.
    Type: Application
    Filed: December 3, 2013
    Publication date: June 26, 2014
    Applicant: Instituto Nacional De Tecnologia Agropecuaria (Inta)
    Inventors: Thomas SURREY, Aurelien OLICHON, Lorena Laura GARAICOEACHEA, Gisela Ariana MARCOPPIDO, Gladys Viviana PARREÑO, Silvia GÓMEZ SEBASTIÁN, José Angel MARTÍNEZ ESCRIBANO, Andrés WIGDOROVITZ
  • Publication number: 20140170163
    Abstract: Provided herein are methods of producing neutralizing monoclonal antibodies, by cyclical immunization, that cross-react with strains of Influenza virus of the same subtype or different subtypes. Also provided herein are compositions comprising such antibodies and methods of using such antibodies to diagnose, prevent or treat Influenza virus disease.
    Type: Application
    Filed: January 23, 2014
    Publication date: June 19, 2014
    Applicant: MOUNT SINAI SCHOOL OF MEDICINE
    Inventors: Adolfo Garcia-Sastre, Peter Palese, Taia T. Wang
  • Patent number: 8753623
    Abstract: The present invention discloses isolated peptides encoding an antigen or fragments thereof from the N-terminus of hemagglutinin protein of influenza, methods for isolating such antigens and specific uses thereof. The peptide can be used as a vaccine to generate an antibody response that neutralizes influenza infectivity against a variety of influenza strains.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: June 17, 2014
    Inventors: Runtao He, Xuguang Li, Gary Van Domselaar
  • Publication number: 20140161822
    Abstract: The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.
    Type: Application
    Filed: November 12, 2013
    Publication date: June 12, 2014
    Applicant: Genentech, Inc.
    Inventors: Min XU, Mercedesz BALAZS, Ning CHAI, Nancy Chiang, Henry CHIU, Zhaoyu JIN, Zhonghua LIN, Patrick LUPARDUS, Gerald R. NAKAMURA, Hyunjoo PARK, Lee SWEM
  • Patent number: 8747856
    Abstract: The present invention relates to the use of a fully human antigen binding fragment of an antibody for the manufacture of a medicament for the treatment or diagnosis of an ocular disease upon topical administration. The invention further relates to a pharmaceutical composition comprising a fully human binding fragment of an antibody for ocular topical administration for treatment or diagnosis of an ocular disease. In particular, the antibody neutralizes HSV1 and HSV2.
    Type: Grant
    Filed: May 4, 2010
    Date of Patent: June 10, 2014
    Assignee: Ribovax Biotechnologies S.A.
    Inventors: Claire Abadie, Jean-Marc Combette, Catherine Deloche, Robert Anthony Williamson
  • Patent number: 8735346
    Abstract: The present invention relates to Hepatitis C virus (HCV)-derived polypeptides and nucleic acid molecules encoding same which advantageously comprises a cd81-binding region. In this connection, the present invention specifically relates to the use of the polypeptides or nucleic acid molecules in compositions and methods for the prevention, the treatment and the diagnosis of HCV infections.
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: May 27, 2014
    Assignee: Institut Pasteur
    Inventors: Thomas Krey, Felix A. Rey, Carlos Massayuki Kikuti, Laurence Damier-Piolle
  • Publication number: 20140134604
    Abstract: Replicons of genotype 6 hepatitis C virus (HCV) are provided. These replicons contain adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 6 replicons and methods of using these replicons to screen antiviral agents are also provided.
    Type: Application
    Filed: November 6, 2013
    Publication date: May 15, 2014
    Inventors: Guofeng Cheng, William E. Delaney, IV, Betty Peng, Mei Yu
  • Patent number: 8722341
    Abstract: Provided is an isolated mammalian negative strand RNA virus, metapneumovirus (MPV). Described are isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. Also described is mammalian MPV, subgroups and variants thereof, and genomic nucleotide sequences of different isolates of mammalian metapneumoviruses, in particular human metapneumoviruses. The use of the sequence information of different isolates of mammalian metapneumoviruses for diagnostic and therapeutic methods is provided. Nucleotide sequences encoding the genome of a metapneumovirus or a portion thereof, including both mammalian and avian metapneumovirus are described. Also provided are chimeric or recombinant viruses encoded by said nucleotide sequences and chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences.
    Type: Grant
    Filed: December 31, 2008
    Date of Patent: May 13, 2014
    Assignees: ViroNovative B.V., MedImmune Vaccines, Inc.
    Inventors: Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus Dominicus Marcellinus Erasmus Osterhaus, Aurelia Haller, Roderick Tang
  • Patent number: 8716454
    Abstract: The present invention features solid compositions comprising Compound IA, IB or IC, or a pharmaceutically acceptable salt thereof, in an amorphous form. In one embodiment, Compound IA, IB or IC, or a pharmaceutically acceptable salt thereof, is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: May 6, 2014
    Assignee: Abbvie Inc.
    Inventors: Simon Kullmann, Ulrich Westedt, Mirko Pauli, Rudolf Schroeder, Gerd Woehrle, Tanja Heitermann, Renato Koenig, Madlen Thiel, Yi Gao, Jianwei Wu, Bryan K. Erickson
  • Publication number: 20140120113
    Abstract: The present disclosure relates to binding molecules, such as human monoclonal antibodies, that bind to an epitope in the stem region of hemagglutinin of influenza A viruses of phylogenetic group 1 and group 2, as well as influenza B viruses, and have a broad neutralizing activity against such influenza viruses. The disclosure provides nucleic acid molecules encoding the binding molecules, their sequences and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of influenza A viruses of phylogenetic groups 1 and 2, as well as influenza B viruses.
    Type: Application
    Filed: July 12, 2012
    Publication date: May 1, 2014
    Applicant: Crucell Holland B.V.
    Inventors: Theodorus Hendrikus Jacobus Kwaks, David Adrianus Theodorus Maria Zuijdgeest, Ronald Vogels, Robert Heinz Edward Friesen
  • Patent number: 8709779
    Abstract: The characterization of a new strain of human rhinovirus of genetic group C (HRV-C) as well as methods and kits for detecting the presence of HRV-C by PCR amplification are provided.
    Type: Grant
    Filed: April 16, 2009
    Date of Patent: April 29, 2014
    Assignees: Biomerieux, Institute of Pathogen Biology, Chinese Academy of Medical Sciences, Beijing Children's Hospital Affiliated to Capital Medical University
    Inventors: Richard Gonzalez, Jianwei Wang, Zichun Xiang, Kunling Shen
  • Publication number: 20140112936
    Abstract: Isolated, antigenic polypeptides including a pre-hairpin intermediate conformation of gp41 and vectors encoding such polypeptides are provided. Antibodies that bind to a pre-hairpin intermediate conformation of gp41 and methods of making antibodies a that bind to pre-hairpin intermediate conformation of gp41 are also provided. Vaccines against a pre-hairpin Fd intermediate conformation of gp41, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided. Methods of screening compounds that bind to an isolated, pre-hairpin intermediate conformation of gp41 are further provided.
    Type: Application
    Filed: November 9, 2011
    Publication date: April 24, 2014
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Bing Chen, Gary H. Frey, Jia Chen
  • Publication number: 20140093500
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Application
    Filed: September 27, 2013
    Publication date: April 3, 2014
    Applicant: MEDIMMUNE LIMITED
    Inventors: Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda
  • Publication number: 20140087362
    Abstract: Diagnostic methods for in vivo and ex vivo detection of circulating tumor cells (CTCs) for the diagnosis and treatment of cancer are provided. The diagnostic methods employ oncolytic viruses alone or in combination with one or more tumor cell enrichment and/or detection methods. Combinations and kits for use in the practicing the methods also are provided.
    Type: Application
    Filed: March 13, 2013
    Publication date: March 27, 2014
    Inventors: Aladar A. Szalay, Nanhai G. Chen, Huiqiang Wang, Melody Fells, Albert Roeder, Qian Zhang, Boris Minev
  • Publication number: 20140079731
    Abstract: The invention contemplates a new synthetic, codon-optimized Sin Nombre virus (SNV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The SNV ORF was cloned into a plasmid to form the first stable recombinant SNV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a vaccine system, and is useful to protect mammals against infection with Sin Nombre virus.
    Type: Application
    Filed: January 31, 2011
    Publication date: March 20, 2014
    Applicant: The United States of America as rep. by the Sec'y the army for U.S. Army Medical Research Institute
    Inventor: Jay Hooper
  • Publication number: 20140072575
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: September 13, 2013
    Publication date: March 13, 2014
    Applicant: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • Patent number: 8669046
    Abstract: Antibodies that specifically bind to a peptide having an amino acid sequence as found at the N-terminus of the HA2 fusion peptide of the influenza A virus may be raised by inoculating a mammal with a conjugate of the peptide. In one embodiment, the conjugate comprises the peptide linked to a spacer (e.g. 6-aminocaproic acid) and a carrier protein (e.g. KLH). The antibodies may be used as a universal reagent for detecting HA proteins of influenza viruses. The antibodies are useful as versatile reagents for laboratory research and vaccine potency determination, especially in the event of pandemic influenza outbreaks.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: March 11, 2014
    Inventors: Xuguang (Sean) Li, Runtao He, Gary Van Domselaar
  • Publication number: 20140065165
    Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.
    Type: Application
    Filed: October 10, 2013
    Publication date: March 6, 2014
    Applicant: Crucell Holland B.V.
    Inventors: Ronald Vogels, Theodorus H. J. Kwaks
  • Publication number: 20140065599
    Abstract: Provided is a new polyomavirus, provisionally named MX polyomavirus, (MXPyV). Further provided are cDNA nucleic acid sequences, recombinant proteins, expression vectors and host cells, recombinant anti-MXPyV antibodies, vaccines, compositions, methods of detecting MXPyV, methods for assaying for anti-MXPyV compounds, and methods for treating or preventing a MXPyV infection.
    Type: Application
    Filed: August 22, 2013
    Publication date: March 6, 2014
    Inventors: Charles CHIU, Guixia Yu, Alexander Greninger, Pavel Isa, Carlos F. Arias, Joseph De Risi, Juliet Parsonnet, Steve Miller
  • Publication number: 20140065166
    Abstract: The invention described herein provides novel peptides. The novel peptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Nipah virus and/or Hendra virus.
    Type: Application
    Filed: April 9, 2013
    Publication date: March 6, 2014
    Applicant: The Henry M. Jackson Foundation for the Advancemen t of Military Medicine, Inc.
    Inventors: Christopher C. Broder, Deborah L. Fusco, Kai Hu, Dimitar B. Nikolov